VH-298

Item no.	HY-100947-100mg
Manufacturer	MedChem Express
CASRN	2097381-85-4
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 2 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Testicular & Prostate Cancer Renal Cancer
Type	Inhibitors
Specific against	other
Purity	99.83
Citations	[1]Frost J, et al. Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition. Nat Commun. 2016 Nov 4;7:13312.
Smiles	O=C([C@H]1N(C([C@H](C(C)(C)C)NC(C2(CC2)C#N)=O)=O)C[C@H](O)C1)NCC3=CC=C(C4=C(C)N=CS4)C=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	2097381-85-4
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Targets	HIF/HIF Prolyl-Hydroxylase; Ligands for E3 Ligase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	523.65
Product Description	VH-298 is a highly potent inhibitor of the VHL:HIF-α interaction with a Kd value of 80 to 90 nM. VH-298 leads to HIF-α accumulation inside HeLa cells. VH-298 is an E3 ligase Ligand, and can be used for synthesis of PROTACs[1].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO: ≥ 83.3 mg/mL
Manufacturer - Pathway	Metabolic Enzyme/Protease; PROTAC
Isoform	von Hippel-Lindau (VHL)
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100947-100mg-safety-datasheet.pdf